Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged

Core Insights - Sanofi reported a third-quarter profit that exceeded analysts' expectations, driven by strong demand for its anti-inflammatory drug Dupixent and newer medicines [1] Company Performance - The strong performance in the third quarter was primarily attributed to the sales growth of Dupixent, which indicates robust market demand for the drug [1] - The introduction of newer medicines also contributed positively to the company's overall profit [1]